Document is current
Any future updates will be listed below
-
Authors
Wölfle, Uta Christine
Beck, Franziska
Werner, Nils
Pitchika, Vinay
Heck, Katrin
Folwaczny, Matthias
Schwendicke, Falk
Boudriot, Emanuel
Greiner, Sophie-Kathrin
Hasan, Alkomiet
Falkai, Peter
Löhrs, Lisa
Bumm, Caspar Victor
-
Funding
Funding for this research was provided by:
Klinikum der Universität München
- License Information
-
More Information
Article History
Received: 25 April 2025
Accepted: 14 July 2025
First Online: 6 August 2025
Declarations
:
: SKG serves on the advisory board of the Goldkind Foundation (Goldkind Stiftung). This position has no influence on the presented research, its analysis, or conclusions. AH has served on advisory boards for Boehringer Ingelheim, Lundbeck, Janssen, Otsuka, Rovi, Teva, AbbVie and Recordati and has received speaking honoraria from these companies as well as AbbVie and Advanz. He is editor of the German S3 guideline on schizophrenia. PF received research support/honoraria for lectures or advisory activities from: Boehringer-Ingelheim, Janssen, Lundbeck, Otsuka, Recordati and Richter. The other authors declare no potential conflicts of interest with respect to the authorship and publication of this article, including financial interests and the provision of study materials by the manufacturer for free or at a discount.
: The authors declare no competing interests.
